Substituted quinazoline compounds
    4.
    发明授权
    Substituted quinazoline compounds 失效
    取代喹唑啉化合物

    公开(公告)号:US08389530B2

    公开(公告)日:2013-03-05

    申请号:US13142333

    申请日:2009-12-18

    CPC分类号: C07D401/14 C07D403/04

    摘要: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

    摘要翻译: 本发明涉及某些新化合物,其制备方法和用于治疗或改善激酶介导的病症的方法。 更具体地,本发明涉及可用作选择性激酶抑制剂的取代喹唑啉化合物,用于制备这些化合物的方法和用于治疗或改善激酶介导的病症的方法。特别地,所述方法涉及治疗或改善激酶介导的病症,包括 心血管疾病,糖尿病,糖尿病相关疾病,炎性疾病,免疫学障碍,癌症和眼睛疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病等。